Novartis discontinues Phase 3 trial of XOMA-licensed NIS793 in pancreatic cancer; continues in colorectal cancer

XOMA Royalty Corp

Novartis stopped Phase 3 trial (NCT04935359) of NIS793 in first-line metastatic PDAC based on benefit-risk assessment.
Trial compared NIS793 plus gem/nab-paclitaxel vs placebo plus gem/nab-paclitaxel; no efficacy or safety established.
Novartis will continue investigating NIS793 in other indications, including a Phase 2 study in colorectal cancer.
XOMA licensed NIS793 to Novartis in September 2015 under a license agreement previously filed with the SEC.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.